tbuckley/cabot-search huggingface dataset:
AB1518 INCIDENTALLY FOUND INTERSTITIAL LUNG DISEASE MAY NOT BE UNCOMMON IN FAMILIAL MEDITERRANEAN FEVER
Authors: S. Acer Kasman, N. Şen, T. Baysal, R. Dizman, S. Yilmaz-Oner, M. E. Tezcan
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by episodes of serositis and fever. Pleuritis is one of the common findings especially during attacks and thorax scans. However, data on other common lung findings such as interstitial lung disease (ILD) are limited in the literature. <h3>Objectives</h3> Here, we present the frequency of ILD and factors associated with ILD in our FMF cohort. <h3>Methods</h3> We included 242 patients who applied to the rheumatology outpatient clinic of a tertiary medical center within the last five years and were requested to undergo thoracic CT for any reason. The patients with a history of malignancy, active infection, active tuberculosis, or tuberculosis history, active or history of coronavirus 19 disease (COVID-19), nursing and pregnancy were excluded. An experienced radiologist blindly evaluated thoracic CT scans for ILD in accordance with relevant guidelines. We then evaluated the relationship between ILD findings and demographics and disease characteristics. <h3>Results</h3> Eleven (4.5%) of 242 patients had ILD. The most common ILD-related findings on thoracic CT were ground glass opacity (7/11 patients). None of the patients had honeycomb appearance. The most common reasons for requesting a thoracic CT were chest/chest pain, suspected COVID-19, and chronic cough. In addition, none of the demographic and disease-related characteristics were associated with ILD in our FMF patients (Table 1). <h3>Conclusion</h3> We have shown that incidentally diagnosed ILD is not uncommon in our FMF patients. In addition, FMF feature may not be associated with ILD in our patients. <h3>Reference</h3> [1]Lidar, M., et al., <i>Thoracic and lung involvement in familial Mediterranean fever (FMF).</i> Clin Chest Med, 2002. 23(2): p. 505-11. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0476 AFTER JAK INHIBITOR FAILURE, ‘SWITCHING’ OR ‘CYCLING’?
Authors: P. Muñoz Martinez, L. Mas Sanchez, E. Grau García, A. M. Torrat Noves, D. Ramos Castro, C. Riesco Barcena, A. V. Huaylla Quispe, S. Leal Rodriguez, I. Cánovas Olmos, H. Charia, L. Gonzalez Puig, J. Ivorra Cortés, I. Martínez Cordellat, C. Nájera Herranz, R. Negueroles Albuixech, J. E. Oller Rodríguez, F. Ortiz-Sanjuán, E. Tovar-Sugrañes, E. Vicens Bernabeu, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The appearance of JAK inhibitors (JAKi) in the last few years has proved a great clinical application in rheumatic pathology and it has become an innovative and widely used therapeutic line. Nevertheless, the evidence of therapeutic alternatives in real life after the failure of a first JAK inhibitor is limited: a second JAKi or the change in therapeutic target. <h3>Objectives</h3> To analyze the treatment alternatives after JAKi failure in real life conditions. <h3>Methods</h3> Retrospective longitudinal observational study of patients that started JAKi treatment later discontinued between 2013 and 2022. Demographic and clinical variables were collected from the electronic medical record. 'Switching' and 'cycling' were analyzed depending on the prescribed therapy after the JAKi, classifying them in the following targets: anti-TNF, anti-IL6, anti-CTLA4, anti-IL12/23, anti-IL17, anti-IL23, another JAKi or other situations. <h3>Results</h3> Out of 265 JAKi prescriptions, 95 failures to JAKi treatment were included in this study. The most recurrent indication was Rheumatoid Arthritis (n=71), and the JAKi with higher failure rate was tofacitinib (n=61), with an average follow-up of 6 months (see Table 1). The most frequent cause of end of treatment was adverse reaction (34.74%), followed by secondary failure (28.42%) and primary failure (21.05%). After all the JAKi failures, cycling another JAKi was the most frequent therapeutical choice (n=25), followed by a switching to other families like anti-TNF (n=16) or anti-IL6 (n=15). <h3>Conclusion</h3> After a first JAKi failure, cycling another JAKi is the most recurrent alternative in our series, used most frequently in patients that present a secondary failure. Switching was the most frequent alternative used with patients who stopped receiving the treatment due to side effects. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0462 COMPARING INJECTION OF LOCAL ANESTHESIA IN OVERLYING SKIN TO NOT GIVING IT PRIOR TO INTRAARTICULAR INJECTION OF GLUCOCORTICOID - A RANDOMIZED CONTROLLED TRIAL
Authors: V. Dhir, A. Shaji, C. B. Prasad, G. Naidu, A. Sharma, S. K. Sharma, S. Jain, S. Bhutungru, B. Ghai
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> There is no consensus among rheumatologists on giving local anesthesia to the overlying skin prior to an intra-articular injection of glucocorticoid. <h3>Objectives</h3> Compare procedural pain in intra-articular injection between using local anesthesia to overlying skin or not. <h3>Methods</h3> Open label randomized controlled trial included patients with rheumatoid arthritis or spondyloarthritis undergoing intra-articular injections (of glucocorticoid) to paired medium-large joints. First the left joint was injected followed by right joint after a gap of 10-minutes. Randomization was done by online software using serial permuted blocks of varying sizes (4, 6 and 8) whether local anesthesia (5 ml of 2% Lignocaine using a 23G needle) would be given to the left or right joint. Primary endpoint was immediate procedural pain felt by the patient using the 'Numerical Rating Scale and Faces Pain Scale-Revised. Secondary endpoints were 1-hour pain assessment, patient preference and complications. Paired t-test and Wilcoxon Signed Ranked test was used (paired data). Trial#CTRI/2021/07/034777 <h3>Results</h3> This study included 42 patients undergoing paired joint injections (84 joints); joints were knee (21 patients. 42 joints), wrists (14 patients, 28 joints), ankles (5 patients, 10 joints) and elbows (2 patients, 4 joints). In 21 patients, the left joint was given local anesthesia and in the other 21 patients, the right Joint was given local anesthesia. Most had rheumatoid arthritis (37) and minority had spondyloarthritis [5]. Their mean age (±SD) was 44.6 ± 14 years and 71% were females. There was a significantly lower immediate procedural pain in the joint over which the skin was given local anaesthesia compared to that not (4.7 (1.7), 5.6 (1.6), p&lt;0.01, difference -1.1, 95% CI -1.5 to -0.7) (Table 1, Figure 1A). This was also reduced pain at 1-hour post procedure (3.3 (1.4), 4.0 (1.6), p&lt;0.01). Majority of patients (78.6%) preferred the procedure with local anaesthesia (Figure 1B). There was no difference in complications of hypopigmentation or purpura nor in residual pain prick-site at 1-month. <h3>Conclusion</h3> Local anaesthesia of the overlying skin led to a definite but modest reduction in pain felt by the patient during intraarticular injection. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1335 ASSOCIATION BETWEEN LIPID PROFILE AND RISK OF INCIDENT SYSTEMIC SCLEROSIS: A NATIONWIDE POPULATION-BASED STUDY
Authors: O. C. Kwon, K. D. Han, M. C. Park
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Lipid metabolism is altered in patients with systemic sclerosis (SSc), mediating activation of immune cells and fibroblasts. However, it is unclear whether altered lipid profile in individuals without SSc is associated with a risk of future development of SSc. <h3>Objectives</h3> To assess the association between lipid profile and future development of SSc. <h3>Methods</h3> Individuals without SSc who underwent national health check-ups in 2009 were selected and followed up through 2019 from a nationwide database of the Korean National Health Insurance Service. Serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride, measured on the date of health check-up in 2009, were each categorized into quartiles (Q1 [lowest], Q2, Q3, and Q4 [highest]). Individuals who developed SSc during follow-up were identified. Cox regression analyses adjusted for multiple covariates were performed to estimate the adjusted hazard ratios (aHRs), and 95% confidence intervals (CIs) according to the quartiles of levels of TC, HDL-C-, LDL-C, and triglyceride, respectively, using Q1 as the reference. <h3>Results</h3> Of the 9,894,996 individuals selected, 1,355 individuals developed SSc during a mean follow-up of 9.2 years, accounting for an incidence rate of 1.49 per 100,000 person-years. Compared with Q1 levels, Q4 levels of TC (aHR 0.691, 95% CI 0.592–0.806), HDL-C (aHR 0.611, 95% CI 0.521–0.716), and LDL-C (aHR 0.735, 95% CI 0.630–0.856) were associated with a lower risk of incident SSc, while Q4 levels of triglyceride (aHR 1.060, 95% CI 0.896–1.254) were not. Higher quartiles of TC (p for trend&lt;0.001), HDL-C (p for trend&lt;0.001), and LDL-C (p for trend=0.001) were associated with a larger effect size. <h3>Conclusion</h3> Serum levels of TC, HDL-C, and LDL-C were inversely associated with the risk of incident SSc. Our findings provide new insights that altered lipid profile could be considered a risk factor for incident SSc. <h3>Reference</h3> None. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1835-HPR WHAT IS THE ROLE OF RHEUMATOLOGY NURSES IN THE MANAGEMENT OF GOUT PATIENTS IN PRACTICE? A MULTICENTRIC MOROCCAN STUDY
Authors: F. Kronbi, H. Rkain, S. Ez-Zaoui, T. Latifa, S. Bahloul, S. Farih, F. El Joumani, R. Honsali, I. Bensaghir, N. Alami, N. Hajjaj-Hassouni, F. Allali
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background:</h3> <h3>Objectives</h3> The aim of this study was to assess nurses' skill level and educational needs on gout disease. <h3>Methods</h3> This is a multicenter cross-sectional study carried out in 10 rheumatology departments in different university hospitals in Morocco. We invited nurses working in those departments to participate in the study. Nurses answered to a questionnaire provided data on their professional activity and socio-demographic status. The questionnaire collected also nurses' management skills on gout disease including systematic measurement of the different clinical parameters of patients, visual pain analogic scale (VAS) pain, collecting comorbidities, identification and verification of adherence to the treatment, therapeutic education of patients and treatment side effects notification. <h3>Results</h3> Our study has included 45 nurses (mean age of 34.2 years, 77.8% females). The mean work duration at a rheumatology department was 7.2 ± 4.6. Table 1 summarized assessment results of the competencies which are required for the management of patients suffering from gout. <h3>Conclusion</h3> Gout is the prototype of chronic diseases where the nurse plays a central role in the multidisciplinary care of patients. We realize through our study the urgent need to remedy to alarming shortcomings in nurses management of patients suffering from gout. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
HIV infection and engagement in the care continuum among migrants and refugees from Venezuela in Colombia: a cross-sectional, biobehavioural survey
Authors: Andrea L Wirtz, José Rafael Guillén, Megan Stevenson, Jennifer Ortiz, Miguel Ángel Barriga Talero, Kathleen R Page, Jhon Jairo López, Damary Martínez Porras, Jhon Fredy Ramirez Correa, Ricardo Luque Núñez, Julián A Fernández-Niño, Paul B Spiegel
Journal: The Lancet HIV (2023)
AB0752 REMAINING UNMET NEEDS FOR THE TREATMENT AND MANAGEMENT OF GIANT CELL ARTERITIS
Authors: E. Hettel, M. Yarnall, K. Murray
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatologists face significant challenges in the management of giant cell arteritis (GCA), with a limited armamentarium of treatment options. Physicians are largely dependent on the use of glucocorticoids, with tocilizumab being the only available advanced systemic agent for the treatment of giant cell arteritis. <h3>Methods</h3> An independent market analytics firm collaborated with 102 US rheumatologists to conduct an analysis of the GCA market. Data were collected via an online survey and supplemented with 8 qualitative interviews, all fielded June 16 through July 13, 2022. Research stimuli included physician demographics, patient management, use and perceptions of current treatments, as well as perceptions of potential new assets in development for GCA. <h3>Results</h3> The desire to minimize use of glucocorticoids is currently the greatest treatment challenge in the management of GCA. Although rheumatologists recognize the benefits of initiating newly diagnosed patients on glucocorticoids for the prevention of disease progression, including blindness caused by GCA, the negative side effects caused by long-term use gives physicians concern. While tocilizumab is used in patients with and without cerebral or ocular symptoms, most rheumatologists still rely heavily on the use of glucocorticoids, accounting for 89% of patient prescriptions in GCA, an aspect largely driven by a lack of availability for other advanced therapies. Of patients prescribed tocilizumab, 65% of patients were initiated on the drug in combination with glucocorticoids. Interviewed prescribers indicate difficulty in tapering glucocorticoids for patients on combination therapy, aiding in the desire for more steroid-sparing treatment options. Rheumatologists are excited to see new agents in development for GCA. Preference is highest for an IL-17A inhibitor, making secukinumab the leading drug of interest. Physicians also perceive secukinumab to be more of an advance over tocilizumab than upadacitinib or guselkumab. <h3>Conclusion</h3> With rheumatologists continuing to use tocilizumab in GCA, there is still a high need to reduce the use of steroids and for new mechanisms of actions to become available for this patient population. Physicians are eager to expand the current GCA armamentarium and anticipate these potential new agents to make have a positive impact on their management of GCA. <h3>References</h3> [1]Kara Murray, Emily Hettel and Maxine Yarnall are employees of Spherix Global Insights, an independent market intelligence firm, and have received no industry funding to conduct and report on this study. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1064 PRE-DIABETES INCREASED THE RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A POPULATION-BASED COHORT STUDY
Authors: H. Meng, H. So, S. H. M. Lam, L. S. Tam
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Pre-diabetes was associated with an increased risk of all-cause mortality and cardiovascular disease (CVD) in the general population. However, data exploring the effect of pre-diabetes on the risk of CVD in patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and psoriatic arthritis (PsA), were limited. <h3>Objectives</h3> To evaluate the effect of pre-diabetes on the risk of major cardiovascular events (MACE) in patients with IA. <h3>Methods</h3> A population-based cohort of IA patients was identified in the citywide platform (The Hospital Authority Data Collaboration Lab) of the Hong Kong Hospital Authority. IA patients recruited from 2006 to 2015 were followed until the end of 2018. Time-varying Cox proportional hazard models with time-varying fasting glucose (FG) levels were analyzed to identify the risk of having MACE in IA patients. <h3>Results</h3> A total of 13,905 (12,233 RA and 1,672 PsA) patients with IA were recruited. After a total of 119,571 patient-years of follow-up, 934 (7.0 %) patients developed a first MACE. At baseline, the mean age of the entire cohort was 56.9±14.4 (RA: 57.7±14.4 vs. PsA: 51.0±12.8, <i>p</i>&lt;0.001), mean disease duration was 0.6±1.5 (RA: 0.7±1.5 vs. PsA: 0.3±1.0, <i>p</i>&lt;0.001) and the proportion of patients with diabetes was 3.6% (RA: 3.4 vs. PsA: 5.4, <i>p</i>&lt;0.001). Using multivariable Cox regression analysis, in IA patients who were not on any anti-diabetic medications, the time-varying FG level of a prediabetic state (5.6-6.9 mmol/L) was found to be independently associated with a higher risk of MACE (HR 2.54, 95%CI 1.50-7.71, <i>p</i>&lt;0.001 in the ESR model; HR 2.43, 95%CI 1.97-2.99, <i>p</i>&lt;0.001 in the CRP model) (Table 1), after adjusting for age, sex, and baseline cardiovascular comorbidities and treatment. On the other hand, in patients already on anti-diabetic treatments, MACE risks were similar between patients with FG levels &lt;5.6 mmol/L and prediabetes. <h3>Conclusion</h3> Pre-diabetes, as reflected by FG level at 5.6-6.9 mmol/L over time, was independently associated with an increased risk of MACE. <h3>Reference</h3> [1] Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. Bmj. 2020;370. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS1096 ASSESSMENT OF PERCEPTION OF BENEFITS AND BARRIERS TO EXERCISE PARTICIPATION AMONG PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES AND HEALTHY INDIVIDUALS: A CASE CONTROL STUDY
Authors: A. Adnine, F. Z. Taik, N. Takhrifa, F. Z. Aharrane, N. Soba, M. Fourtassi, F. E. Abourazzak
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Benefits of regular physical activity (PA) are well known and well publicized. Despite the many benefits of PA, patients with chronic inflammatory rheumatic diseases (CIRD) report low levels of PA and engage more in sedentary behavior. <h3>Objectives</h3> We aim to assess the perception levels of benefits and barriers to exercise participation among patients with CIRD and healthy individuals and examine the predictors of poor perception levels. <h3>Methods</h3> A cross-sectional study was performed among patients with CIRD Aged between 18 and 65 years old who visited the outpatient clinic. Healthy controls were recruited in a specialized consultation. Socio-demographic and clinical findings were collected. Physical activity levels were assessed using (IPAQ). Perceived benefits and barriers to exercise scale (PBBS) was used to assess the perception of patients and healthy controls toward exercise. Furthermore, all participants underwent screening for anxiety and depressive disorders using (PHQ-9) and (GAD-7) respectively. <h3>Results</h3> 172 patients were enrolled in the study (92 RA, 65 SpA and 15 Undifferentiated CIRD) and 159 healthy controls. <h3>Conclusion</h3> We found that patients with CIRD perceive significantly less benefits and more barriers to exercise participation than healthy individuals. Barriers to physical activity in both groups are related to physical exertion, thus we highlight the role of adapted PA especially in patients with CRID. Depressive disorders is known to alter perception of reality in a negative way [1]. Education about the diagnosis and treatment of depressive disorders is essential to promote PA [2]. <h3>References</h3> [1]Kalmár S. Disturbance of perception in depressive disorders in the different diagnostical systems. Neuropsychopharmacol Hung. 2009 Dec;11(4):227-34. PMID: 20150660. [2]Tuso P. Strategies to Increase Physical Activity. Perm J. 2015 Fall;19(4):84-8. doi: 10.7812/TPP/14-242. PMID: 26517440; PMCID: PMC4626000. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial
Authors: Frank Siebenhaar, Sabine Altrichter, Hanna Bonnekoh, Tomasz Hawro, Marlena Hawro, Edward G Michaelis, Andrea M Kantor, Alan T Chang, Bradford A Youngblood, Bhupinder Singh, Henrik S Rasmussen, Marcus Maurer
Journal: British Journal of Dermatology (2023)

Indolent systemic mastocytosis (ISM) is characterized by excessive mast cell (MC) accumulation and MC-driven signs and symptoms. Currently used therapies are not approved and have limited efficacy. Lirentelimab (AK002) is a monoclonal antibody against sialic acid-binding immunoglobulin-like lectin (Siglec)-8 that inhibits MC activation.To determine the safety, tolerability and efficacy of lirentelimab in reducing the symptoms of ISM.At a specialty centre for mastocytosis in Germany, we conducted a phase I first-in-human single-ascending and multidose clinical trial of lirentelimab in patients with ISM. Eligible adults had World Health Organization-confirmed ISM and an unsatisfactory response to available treatment. In part A, patients received a single dose of lirentelimab 0.0003, 0.001, 0.003, 0.01 or 0.03 mg kg-1; in part B, patients received one lirentelimab dose of 0.3 mg kg-1 or 1.0 mg kg-1; and in part C, patients received either 1.0 mg kg-1 lirentelimab every 4 weeks for 6 months or ascending doses of lirentelimab (one dose of 1 mg kg-1 followed by five doses of 3-10 mg kg-1 every 4 weeks). The primary endpoint was safety/tolerability. Secondary endpoints included changes from baseline in Mastocytosis Symptom Questionnaire (MSQ), Mastocytosis Activity Score (MAS) and Mastocytosis Quality of Life Questionnaire (MC-QoL) scores at 2 weeks after the final dose.In 25 patients with ISM (13 in parts A + B and 12 in part C; median age 51 years, 76% female, median 4.6 years from diagnosis), the most common treatment-related adverse events (AEs) were feeling hot (76%) and experiencing a headache (48%). No serious AEs occurred. Median MSQ and MAS symptom severity scores in part C improved (vs. baseline) across all symptoms [MSQ: skin (38-56%), gastrointestinal (49-60%), neurological (47-59%), musculoskeletal (26-27%); MAS: skin (53-59%), gastrointestinal (72-85%), neurological (20-57%), musculoskeletal (25%)]. Median MC-QoL scores improved across all domains: symptoms (39%), social life/functioning (42%), emotions (57%) and skin (44%).Lirentelimab was generally well tolerated and improved symptoms and quality of life in patients with ISM. The therapeutic potential of lirentelimab should be considered for ISM.